RECURRENT MALIGNANT SOLID NEOPLASM

This early-phase study is testing a new type of cell therapy for people with advanced solid tumors, including melanoma, that have spread and are not responding to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack c…

This early-stage trial is testing three different drug combinations to find safe doses and see if they can help control advanced solid tumors that have spread. The study will enroll about 111 adults with specific genetic features in their cancer. Researchers aim to see if combini…

This study is testing whether combining three different cancer drugs is safe and effective for treating advanced solid tumors that have spread or returned after standard treatments. The three drugs work in different ways: one helps the immune system attack cancer, one blocks tumo…

This trial is a large screening program that matches patients with advanced solid tumors to one of many smaller treatment studies. It uses genetic testing on a patient's tumor to find specific mutations. Patients are then assigned to a drug combination designed to target those mu…

This study is testing a new two-drug combination for children, teens, and young adults whose solid tumors or a rare liver cancer called fibrolamellar carcinoma have come back or stopped responding to standard treatments. The main goals are to find the safest and most effective do…

This study is for people with advanced HER2-positive cancers that have come back or spread. It aims to see if taking two targeted drugs together works better than taking one alone to slow or stop cancer growth. About 70 participants will be randomly assigned to one of the two tre…

This early-stage trial is testing a new drug called CBL0137 in children and young adults (ages 1-21) whose solid tumors, brain tumors, or lymphoma have come back or stopped responding to standard treatments. The main goals are to find the safest dose and see if the drug can help …

This study is testing a new drug called tegavivint in children, teens, and young adults whose solid tumors or lymphomas have come back or haven't responded to other treatments. The main goals are to find the safest dose, understand the side effects, and see if the drug can help s…

This is an early safety study for a new drug called TAK-243 in adults with advanced solid tumors or lymphoma. The main goal is to find the safest dose and understand the side effects. Researchers will give the drug to about 95 patients and closely monitor how their bodies handle …

This study is testing two different drug combinations to find safe doses and see if they can help control cancer in children and young adults whose solid tumors have come back or haven't responded to treatment. In the first part, participants will be assigned to receive either On…

This study is testing a new support program for parents who have advanced cancer that has spread or returned. The program provides education and video sessions to help parents manage stress, talk to their children about cancer, and improve family wellbeing. It is for patients wit…

This study collects leftover tissue and blood samples from cancer patients during their normal medical procedures. The samples are stored and used to create living cancer models in the lab. These models help scientists better understand cancer and test potential new drugs, but pa…

This study aims to understand why some people who have been treated for cancers like ovarian cancer later develop blood cancers or disorders. Researchers will observe 2,000 patients who have had certain cancer treatments to look for genetic and other risk factors. They will colle…

This study aims to collect tumor tissue samples from patients with various cancers to test a new diagnostic platform called Elephas. The goal is to see how accurately this tool can predict whether patients will respond to immunotherapy treatments before they begin. Researchers wi…